Corpus Intelligence IC Memo — MARTIN MEDICAL CENTER 2026-04-26 04:01 UTC
IC Memo — MARTIN MEDICAL CENTER
Investment Committee Memorandum | FL | 521 beds | Grade B | EBITDA uplift $49.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MARTIN MEDICAL CENTER

CCN 100044 | MARTIN, FL | 521 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

MARTIN MEDICAL CENTER is a 521-bed suburban community hospital in MARTIN, FL with $666.5M in net patient revenue and a -0.4% operating margin. The hospital serves a payer mix of 32.0% Medicare, 5.0% Medicaid, and 63.0% commercial.

Thesis: Undervalued. Our ML models identify $49.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.4% to 6.9% (+736bps).

Net Revenue HCRIS$666.5M
Current EBITDA COMPUTED$-2.8M
Operating Margin COMPUTED-0.4%
Occupancy HCRIS73.4%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS18.7%
Distress Probability ML43.2%

2. Market Context & Competitive Position

261
FL Hospitals
3.2%
State Median Margin
69
Comparable Hospitals

FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of -0.4% places it below the state median. Among 69 size-comparable peers (260-1042 beds), the median margin is 5.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (260-1042), prioritizing same-state peers. 69 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MARTIN MEDICAL CENTER (Target)FL521$666.5M-0.4%
UNIVERSITY OF MIAMI HOSP & CLIFL532$2.36B0.9%
UF HEALTH SHANDSFL994$2.24B10.4%
BAPTIST MEDICAL CENTERFL980$1.78B0.9%
TAMPA GENERAL HOSPITALFL898$1.73B-9.3%
BAPTIST HOSPITALFL948$1.71B10.8%
MEMORIAL REGIONAL HOSPITALFL838$1.45B-20.7%
LEE MEMORIAL HOSPITALFL748$1.28B17.4%
SARASOTA MEMORIAL HOSPITALFL787$1.10B8.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $49.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$14.0M+210bp18mo
Cost to Collect4.5%2.5%$13.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$13.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$8.1M+122bp9mo
Clean Claim Rate88.0%96.0%$427K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$14.0M
Cost to Collect
$13.3M
Denial Rate Reduction
$13.2M
A/R Days Reduction
$8.1M
Clean Claim Rate
$427K
Total EBITDA Uplift$49.1M
Current EBITDA$-2.8M
+ RCM Uplift+$49.1M
Pro Forma EBITDA$46.2M
Current Margin-0.4%
Pro Forma Margin6.9%
WC Released (1x)$25.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.3M$472.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.3M$517.8M0.00x-100.0%
Bull Case9.0x11.0x$-3.9M$678.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.9M$738.8M0.00x-100.0%
Bear Case11.0x10.0x$-4.8M$228.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.8M$249.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 69 hospitals with 260-1042 beds
  • Same-state prioritization (n=70)
  • Comp margins: P25=-5.8% / P50=5.7% / P75=19.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.